• News
  • Finance

Daily Digest

Cytori Therapeutics Inc. announced it has received a CE Mark in Europe for Intravase, and Ligand Pharmaceuticals-Cl B announced it received a $1.4 million milestone payment from Retrophin Inc., as part of a licensing agreement signed in February 2012 for the development and commercialization of Retrophin’s lead clinical candidate, RE-021, according to company announcements, SEC filings and Bloomberg News.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!